A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours
Phase of Trial: Phase I/II
Latest Information Update: 28 Sep 2016
At a glance
- Drugs WX 554 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors WILEX AG
- 28 Sep 2016 Results of this trial, published in the European Journal of Cancer.
- 14 Apr 2014 Status changed from recruiting to discontinued, as reported in a Wilex media release.
- 28 Feb 2013 Wilex anticipates that recruitment will be completed by the end of 2013 and results will be presented in the second half of 2014.